psalexa
logo

Cushing’s Syndrome Therapeutics - Pipeline Analysis 2018

Cushing’s Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS10981
Available Format:
Pages: 70

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Cushing’s Syndrome Disease Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Diagnosis

4.1.4 Treatment

4.1.5 Epidemiology

4.2 Key Drivers

4.2.1 Driver 1

4.2.2 Driver 2

4.3 Key Barriers

4.3.1 Barrier 1

4.4 Cushing’s Syndrome Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Cushing’s Syndrome Therapeutics Pipeline Analysis by Phase

5.1 Phase III

5.1.1 Osilodrostat

5.1.1.1 Clinical trials

5.1.2 XXXXX

5.1.2.1 Clinical trials

5.1.2.2 Designation

5.2 Phase II

5.2.1 ATR-101

5.2.1.1 Clinical trials

5.2.2 XXXXX

5.2.2.1 Clinical trials

5.2.3 XXXXX

5.2.4 XXXXX

5.2.4.1 Clinical trials

5.3 Pre-Clinical

5.3.1 AP 102

5.3.1.1 Pre-Clinical trials

5.3.2 XXXXX

5.3.2.1 Pre-Clinical results

5.3.3 XXXXX

5.4 Discovery

5.4.1 Orphan Nuclear Receptor Antagonist - Orphagen Pharmaceuticals Inc.

5.4.2 XXXXX

5.4.3 XXXXX

5.4.3.1 Strategic development

5.5 Unknown

5.5.1 XXXXX

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials, by Region

6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Cushing’s syndrome Therapeutics Pipeline

7.2 SWOT Analysis of Cushing’s Syndrome Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Novartis AG

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 AstraZeneca plc

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 XXXXXX.

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 XXXXXX

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 XXXXXX

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 XXXXXX

8.6.1 Business Overview

8.6.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry